VB10 NEO

Drug Profile

VB10 NEO

Alternative Names: VB10.NEO

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaccibody
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 08 Mar 2018 Paul Ehrlich Institute approves CTA application for a phase I/IIa trial in Solid tumours (In adults, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in Germany (IM)
  • 29 Jan 2018 Central Ethics Committee (Heidelberg) approves CTA for a phase I/IIa trial in Solid tumours (In adults, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in Germany (IM)
  • 25 Jan 2018 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in Germany (IM) (EudraCT2017-002474-39)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top